{1-[3-(4-Fluoro-phenoxy)-propyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone | 148965-78-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: {1-[3-(4-Fluoro-phenoxy)-propyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone
• 英文别名: [1-[3-(4-fluorophenoxy)propyl]piperidin-4-yl]-(4-fluorophenyl)methanone
• CAS: 148965-78-0
• 化学式: C₂₁H₂₃F₂NO₂
• 分子量: 359.416
• InChiKey: KPQATFGUBIQOEE-UHFFFAOYSA-N

物化性质

• 沸点：
  485.1±45.0 °C(predicted)
• 密度：
  1.176±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  {1-[3-(4-Fluoro-phenoxy)-propyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以77%的产率得到1-[3-(4-Fluorophenoxy)propyl]-I+/--(4-fluorophenyl)-4-piperidinemethanol
  参考文献：
  名称：

  7-[3-(1-Piperidinyl)propoxy]chromenones as Potential Atypical Antipsychotics

  摘要：

  Compound 1 (1-benzyl-3-methyl-4-[4-(4-fluorophenyl)- a synthetic intermediate identified as a potential atypical antipsychotic, was selected as the starting point for pharmacological improvement. From 1, sequential structural variations were conducted in order to improve its potency and oral bioavailability. These variations included a series of piperazine, ethanediamine, and piperidine derivatives. The piperidine series afforded some orally potent compounds in the inhibition of apomorphine-induced climbing and hyperactivity in mice, which are regarded as behavioral models predictive of antipsychotic efficacy. Further optimization of these structures led to the highly potent 7-[3-(1-piperidinyl)propoxy]chromenones. Inhibition of stereotypies and induction of catalepsy in rats at doses substantially higher than required for inhibition of climbing suggest an atypical antipsychotic profile, which is assumed to predict a reduced induction of extrapyramidal side effects in humans.

  DOI：

  10.1021/jm950894b
• 作为产物：
  描述：

  4-(4-氟苯甲酰基)哌啶 、 1-(3-氯丙氧基)-4-氟苯 在 potassium carbonate 、 potassium iodide 作用下， 以 乙腈 为溶剂， 反应 24.0h， 以42%的产率得到{1-[3-(4-Fluoro-phenoxy)-propyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone
  参考文献：
  名称：

  7-[3-(1-Piperidinyl)propoxy]chromenones as Potential Atypical Antipsychotics

  摘要：

  Compound 1 (1-benzyl-3-methyl-4-[4-(4-fluorophenyl)- a synthetic intermediate identified as a potential atypical antipsychotic, was selected as the starting point for pharmacological improvement. From 1, sequential structural variations were conducted in order to improve its potency and oral bioavailability. These variations included a series of piperazine, ethanediamine, and piperidine derivatives. The piperidine series afforded some orally potent compounds in the inhibition of apomorphine-induced climbing and hyperactivity in mice, which are regarded as behavioral models predictive of antipsychotic efficacy. Further optimization of these structures led to the highly potent 7-[3-(1-piperidinyl)propoxy]chromenones. Inhibition of stereotypies and induction of catalepsy in rats at doses substantially higher than required for inhibition of climbing suggest an atypical antipsychotic profile, which is assumed to predict a reduced induction of extrapyramidal side effects in humans.

  DOI：

  10.1021/jm950894b

文献信息

• AGENT FOR PROPHYLAXIS AND TREATMENT OF PANCREATITIS
  申请人：Yamaguchi Isamu

  公开号：US20090075974A1

  公开（公告）日：2009-03-19

  Disclosed is a pharmaceutical composition for prophylaxis and treatment of pancreatitis comprising a 5-HT2A receptor antagonist as an effective component, wherein the binding activity (pKi) of the 5-HT2A receptor antagonist to a 5-HT2A receptor is higher at least by 1.0 than the binding activities to a 5-HT2B receptor and a 5-HT2C receptor. Preferably the binding activity (pKi) of the 5-HT2A receptor antagonist to the 5-HT2A receptor is at least 7.0, and more preferably at least 8.0. The present invention also provides a method of identifying a candidate substance for prophylactic and therapeutic agent for pancreatitis, comprising determining whether a test substance has a 5-HT2A receptor antagonistic activity.